Author

Desislava N. Nesheva

Observed names: Desislava Nesheva, Desislava Nikolaeva Nesheva, Nesheva, Desislava

Institutions: Medical University of Sofia, National Museum of History, Vrije Universiteit Amsterdam

Observed institutions: University of Nottingham, Medical University of Sofia, National Museum of History, Luxembourg Institute of Health, Jena University Hospital, Queen's Medical Centre, Friedrich Schiller University Jena, University of Birmingham, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam

ORCID: 0000-0002-7954-3010

Observed ORCID: 0000-0002-7954-3010

OpenAlex ID: A5012016633

Luciferase Complementation Approaches to Measure GPCR Signaling Kinetics and Bias

2021 · Nicola C. Dijon, Desislava N. Nesheva, et al. · Methods in molecular biology · 20

Design, Synthesis, and Application of Fluorescent Ligands Targeting the Intracellular Allosteric Binding Site of the CXC Chemokine Receptor 2

2023 · Bianca Maria Casella, James P. Farmer, et al. · Journal of Medicinal Chemistry · 18

Pharmacological Characterization and Radiolabeling of VUF15485, a High-Affinity Small-Molecule Agonist for the Atypical Chemokine Receptor ACKR3

2024 · Aurelien M. Zarca, Ilze Adlere, et al. · Molecular Pharmacology · 15

ACKR5/GPR182 is a scavenger receptor for the atypical chemokine CXCL17, GPR15L and various endogenous peptides

2024 · Max Meyrath, Christie B. Palmer, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 7

Inhibition of constitutive activity of the atypical chemokine receptor 3 by the small-molecule inverse agonist VUF16840

2025 · Reggie Bosma, Desislava Nesheva, et al. · Molecular Pharmacology · 6

Viewpoints on the First Transatlantic GPCR Symposium for Early-Career Investigators

2021 · Brian J. Bender, Andreas Bock, et al. · ACS Pharmacology & Translational Science · 2

Using NanoBit complementation and TR FRET to Study the Mechanism of Action of Small‐molecule Modulators of CXCR2

2020 · Desislava Nikolaeva Nesheva, Steven Charlton, et al. · The FASEB Journal · 1

The FDA-approved CDK4/6 inhibitor Abemaciclib is a potent agonist of the β-arrestin-biased atypical chemokine receptor ACKR3

2026 · Maurice C.M.L. Buzink, Joy Darcis, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Diastereomer-Dependent Modulation of Atypical Chemokine Receptor 3 (ACKR3) in 3-Azabicyclo[3.1.0]hexane-Based Ligands

2026 · Laura H.A. Wijffelaars, Maurice C.M.L. Buzink, et al. · ChemRxiv

Paleogenomic evidence for genetic heterogeneity and prior admixture in Gothic-associated communities of late antique Bulgaria

2026 · Svetoslav Stamov, Todor Chobanov, et al. · Frontiers in Genetics

Works count: 11

Citation count: 69

H-index: 5

I10-index: 3